Blocking CCL20-CCR6 interaction using CCL20-blocking antibody reduced significantly RM1 tumor growth with no combinatorial effect for anti-PD-1 (Fig. 7e), suggesting CCL20-CCR6 axis to be involved in the prostate immune suppressive TME. This evidence concerns the gene CCR6 and neoplasm.